SAMSRITA LABS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.18 INR | -2.00% |
|
-1.04% | -6.64% |
| Sales 2022 | 2L 2.69T | Sales 2023 | 2L 2.6T | Capitalization | 33Cr 39.67L |
|---|---|---|---|---|---|
| Net income 2022 | 1.5Cr 2L | Net income 2023 | -70L -83.8T | EV / Sales 2022 | 2,001 x |
| Net Debt 2022 | 2.73Cr 3L | Net Debt 2023 | 2.07Cr 2L | EV / Sales 2023 | 1,623 x |
| P/E ratio 2022 |
28.2
x | P/E ratio 2023 |
-46.6
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 19.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.00% | ||
| 1 week | -1.04% | ||
| Current month | -1.16% | ||
| 1 month | -4.77% | ||
| 3 months | +15.90% | ||
| 6 months | -4.71% | ||
| Current year | -6.64% |
1 week
15.27
17.20
1 month
14.1518.00
Current year
13.0019.50
1 year
13.0021.69
3 years
13.0044.15
5 years
13.0075.50
10 years
7.0075.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 14/20/14 | |
K. Krishnam Raju
CHM | Chairman | 65 | 26/16/26 |
V. Someswara Rao
ADM | Chief Administrative Officer | 60 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
K. Krishnam Raju
CHM | Chairman | 65 | 26/16/26 |
| Director/Board Member | - | 22/19/22 | |
| Director/Board Member | 56 | 29/21/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 16.18 | -2.00% | 1 834 |
| 20/24/20 | 16.51 | +4.43% | 5,251 |
| 19/24/19 | 15.81 | +0.25% | 1,054 |
| 18/24/18 | 15.77 | -4.48% | 8,867 |
| 14/24/14 | 16.51 | +0.98% | 1,505 |
Delayed Quote Bombay S.E., June 21, 2024 at 03:31 pm IST
More quotes
Samsrita Labs Ltd is an India-based biopharma company. The Company is engaged activities, such as trading, exports and imports, manufacturing of bulk drugs, APIs, Specialty drugs, research and development (R&D) through joint ventures or associations or mergers or by its own. It has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease.
Calendar
13/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.64% | 29.23L | |
| -15.37% | 854.51Cr | |
| +67.13% | 423.19Cr | |
| +3.72% | 268.49Cr | |
| +0.35% | 261.41Cr | |
| -55.09% | 182.12Cr | |
| -18.08% | 166.15Cr | |
| -21.18% | 141.74Cr | |
| +15.60% | 119.2Cr | |
| -49.14% | 105.36Cr |
- Stock Market
- Equities
- DRHABEEB Stock
